Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy C A
Developmental Endocrinology Branch, NICHD, National Institutes of Health, Bethesda, Maryland 20892, USA.
FASEB J. 2000 Sep;14(12):1725-30. doi: 10.1096/fj.99-0863com.
This study investigated the effect of sex steroids and tamoxifen on primate mammary epithelial proliferation and steroid receptor gene expression. Ovariectomized rhesus monkeys were treated with placebo, 17beta estradiol (E2) alone or in combination with progesterone (E2/P) or testosterone (E2/T), or tamoxifen for 3 days. E2 alone increased mammary epithelial proliferation by approximately sixfold (P:<0.0001) and increased mammary epithelial estrogen receptor (ERalpha) mRNA expression by approximately 50% (P:<0.0001; ERbeta mRNA was not detected in the primate mammary gland). Progesterone did not alter E2's proliferative effects, but testosterone reduced E2-induced proliferation by approximately 40% (P:<0.002) and entirely abolished E2-induced augmentation of ERalpha expression. Tamoxifen had a significant agonist effect in the ovariectomized monkey, producing a approximately threefold increase in mammary epithelial proliferation (P:<0.01), but tamoxifen also reduced ERalpha expression below placebo level. Androgen receptor (AR) mRNA was detected in mammary epithelium by in situ hybridization. AR mRNA levels were not altered by E2 alone but were significantly reduced by E2/T and tamoxifen treatment. Because combined E2/T and tamoxifen had similar effects on mammary epithelium, we investigated the regulation of known sex steroid-responsive mRNAs in the primate mammary epithelium. E2 alone had no effect on apolipoprotein D (ApoD) or IGF binding protein 5 (IGFBP5) expression, but E2/T and tamoxifen treatment groups both demonstrated identical alterations in these mRNAs (ApoD was decreased and IGFBP5 was increased). These observations showing androgen-induced down-regulation of mammary epithelial proliferation and ER expression suggest that combined estrogen/androgen hormone replacement therapy might reduce the risk of breast cancer associated with estrogen replacement. In addition, these novel findings on tamoxifen's androgen-like effects on primate mammary epithelial sex steroid receptor expression suggest that tamoxifen's protective action on mammary gland may involve androgenic effects.
本研究调查了性类固醇和他莫昔芬对灵长类动物乳腺上皮细胞增殖及类固醇受体基因表达的影响。对去卵巢的恒河猴给予安慰剂、单独使用17β-雌二醇(E2)或与孕酮联合使用(E2/P)或与睾酮联合使用(E2/T),或给予他莫昔芬,持续3天。单独使用E2可使乳腺上皮细胞增殖增加约6倍(P<0.0001),并使乳腺上皮雌激素受体(ERα)mRNA表达增加约50%(P<0.0001;在灵长类动物乳腺中未检测到ERβ mRNA)。孕酮未改变E2的增殖作用,但睾酮使E2诱导的增殖降低约40%(P<0.002),并完全消除了E2诱导的ERα表达增加。他莫昔芬在去卵巢的猴子中具有显著的激动剂作用,使乳腺上皮细胞增殖增加约3倍(P<0.01),但他莫昔芬也使ERα表达降至低于安慰剂水平。通过原位杂交在乳腺上皮中检测到雄激素受体(AR)mRNA。单独使用E2时AR mRNA水平未改变,但E2/T和他莫昔芬处理使其显著降低。由于E2/T和他莫昔芬对乳腺上皮具有相似的作用,我们研究了灵长类动物乳腺上皮中已知的性类固醇反应性mRNA的调控。单独使用E2对载脂蛋白D(ApoD)或胰岛素样生长因子结合蛋白5(IGFBP5)表达无影响,但E2/T和他莫昔芬处理组在这些mRNA上均表现出相同的变化(ApoD降低,IGFBP5增加)。这些观察结果表明雄激素诱导乳腺上皮细胞增殖和ER表达下调,提示雌激素/雄激素联合激素替代疗法可能降低与雌激素替代相关的乳腺癌风险。此外,这些关于他莫昔芬对灵长类动物乳腺上皮性类固醇受体表达具有雄激素样作用的新发现表明,他莫昔芬对乳腺的保护作用可能涉及雄激素效应。